Merck's Calderasib Gets FDA Breakthrough Status
Merck's calderasib receives FDA breakthrough therapy designation, potentially accelerating its development and review process. This may impact MRK stock.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.